Teva Pharma (TEVA) Announces New Clinical and Real-World Data Evaluating Efficacy of AJOVY (fremanezumab-vfrm) Injection and Reduction of Migraine Burden

Go back to Teva Pharma (TEVA) Announces New Clinical and Real-World Data Evaluating Efficacy of AJOVY (fremanezumab-vfrm) Injection and Reduction of Migraine Burden
TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) Delayed: 10.15 --0 (-0%)
Previous Close $10.15    52 Week High $66.55 
Open $10.15    52 Week Low $37.82 
Day High $10.15    P/E N/A 
Day Low $10.15    EPS $0.00 
Volume 5,497